The Circulatory Regulation of TPA and UPA Secretion, Clearance, and Inhibition During Exercise and During the Infusion of Isoproterenol and Phenylephrine
- 15 November 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 92 (10) , 2984-2994
- https://doi.org/10.1161/01.cir.92.10.2984
Abstract
Background Exercise to exhaustion and infusions of isoproterenol and phenylephrine were used to study interactions between plasminogen activator regulation and the control of regional blood flow in 10 healthy males. Methods and Results Experimental measurements of cardiac output, heart rate, tissue plasminogen activator (TPA), urokinase plasminogen activator (UPA), plasminogen activator inhibitor (PAI-1), C1-inhibitor, and TPA/C1-inhibitor complex during the infusions and exercise were used to develop a comprehensive fluid-phase model of the circulatory regulation of fibrinolysis. α- and β-adrenergic agonists increased TPA and UPA in plasma by different mechanisms: Phenylephrine decreased hepatic blood flow and thus clearance while isoproterenol stimulated increased secretion of TPA and UPA. Exercise to exhaustion increased TPA and UPA through a combination of increased secretion and decreased clearance. The time course of UPA and TPA release were similar, but the magnitude of their secretion responses differed. In vivo, C1-inhibitor bound to TPA at a rate of 553 mol−1 · s−1. C1-inhibitor contributed equally with PAI-1 to TPA inhibition when active PAI-1 levels were low (20 to 50 pmol/L) but was less important when active PAI-1 levels were high. Conclusions We conclude that secretion, inhibition, clearance, and regional blood flow effects must all be taken into account when evaluating changes in plasminogen activator levels.Keywords
This publication has 56 references indexed in Scilit:
- Endogenous tissue-type plasminogen activator and risk of myocardial infarctionThe Lancet, 1993
- Regulation of the Acute Release of Tissue‐type Plasminogen Activator from the Endothelium by Coagulation Activation ProductsAnnals of the New York Academy of Sciences, 1992
- Fibrinolytic response during exercise and epinephrine infusion in the same subjectsJournal of the American College of Cardiology, 1992
- Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
- Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and strokeThe American Journal of Cardiology, 1988
- Pro-Urokinase: Physiochemical Properties and Promotion of Its Fibrinolytic Activity by Urokinase and by Tissue Plasminogen Activator with which It Has a Complementary Mechanism of ActionSeminars in Thrombosis and Hemostasis, 1988
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- α- and β-receptor blockade of isoproterenol- and norepinephrine-induced effects on regional blood flow and blood flow accelerationEuropean Journal of Pharmacology, 1978
- The plasminogen activator and coagulation factor VIII responses to adrenaline, noradrenaline, isoprenaline and salbutamol in manThrombosis Research, 1973
- Adrenergic Mechanisms in the Systemic Plasminogen Activator Response to Adrenaline in ManBritish Journal of Haematology, 1970